Fluid and Diuretic Therapy in Heart Failure

Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice

Volumn , Issue , 2012, Pages 514-543

  Bonagura, John D ^a   Lehmkuhl, Linda B ^b   Autran de Morais, Helio ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b MedVet Medical and Cancer Center for Pets   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862140033     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0654-3.00028-7     Document Type: Chapter

References (189)

1. Abbott J.A. Beta-blockade in the management of systolic dysfunction. Vet Clin North Am Small Anim Pract 2004, 34:1157-1170.
2. Adin D.B., Taylor A.W., Hill R.C., et al. Intermittent bolus injection versus continuous infusion of furosemide in normal adult greyhound dogs. J Vet Intern Med 2003, 17:632-636.
3. Amberger C.N., Glardon O., Glaus T., et al. Effects of benazepril in the treatment of feline hypertrophic cardiomyopathy: results of a prospective, open-label, multicenter clinical trial. J Vet Cardiol 1999, 1:19-26.
4. Asano K., Masuda K., Okumura M., et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. J Vet Med Sci 1999, 61:523-529.
5. Atkins C.E., Brown W.A., Coats J.R., et al. Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation. J Am Vet Med Assoc 2003, 221:654-658.
6. J Am Vet Med Assoc 2002, 15:1149. (Erratum in, 221.
7. Atkins C.E., Keene B.W., Brown W.A., Coats J.R., Crawford M.A., DeFrancesco T.C., et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007, 231(7):1061-1069.
8. Atkins C., Bonagura J., Ettinger S., Fox P., Gordon S., Haggstrom J., et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009, 23(6):1142-1150.
9. Auld R.B., Alexander E.A., Levinsky N.G. Proximal tubular function in dogs with thoracic caval constriction. J Clin Invest 1971, 50:2150-2158.
10. Barger A.C., Yates F.E., Rudolph A.M. Renal hemodynamics and sodium excretion in dogs with graded valvular damage, and in congestive failure. Am J Physiol 1961, 200:601-608.
11. Bernay F., Bland J.M., Häggström J., Baduel L., Combes B., Lopez A., et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010, 24(2):331-341.
12. J Vet Intern Med 2010, (also see Letter to Editor:, in press.
13. Bonagura J.D., Lehmkuhl L.B. Fluid therapy in heart failure. Fluid therapy in small animal practice 1992, 529-553. WB Saunders, Philadelphia. 1st ed. S.J. DiBartola (Ed.).
14. Bonagura J.D., Ware W.A. Atrial fibrillation in the dog: clinical findings in 81 cases. J Am Anim Hosp Assoc 1986, 22:111-120.
15. Bourland W.A., Day D.K., Williams H.E. The role of the kidney in the early nondiuretic action of furosemide to reduce elevated left atrial pressure in the hypervolemic dog. J Pharmacol Exp Ther 1977, 202:221-229.
16. Bristow M.R. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997, 80:26L-40L.
17. Calvert C.A., Rawlings C.A. Canine heartworm disease. Canine and feline cardiology 1988, 519-549. Churchill Livingstone, New York. P.R. Fox (Ed.).
18. Cannon P.J. The kidney in heart failure. N Engl J Med 1977, 296:26-32.
19. Cataliotti A., Boerrigter G., Costello-Boerrigter L.C., et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004, 109:1680-1685.
20. Chen H.H., Grantham J.A., Schirger J.A., et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000, 36:1706-1712.
21. Clark A.L., Poole-Wilson P.A., Coats A.J. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 1996, 28:1092-1102.
22. Cobb M., Michell A.R. Plasma electrolyte concentrations in dogs receiving diuretic therapy for cardiac failure. J Small Anim Pract 1992, 33:526-529.
23. Cogan M.G. Atrial natriuretic peptide. Kidney Int 1990, 37:1148-1160.
24. Cohn J.N., Levine T.B. Angiotensin-converting enzyme inhibition in congestive heart failure: the concept. Am J Cardiol 1982, 49:1480-1483.
25. Cohn J.N., Levine T.B., Olivar M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
26. Connolly D.J. Natriuretic peptides: the feline experience. Vet Clin North Am Small Anim Pract 2010, 40(4):559-570.
27. Co-operative Veterinary Enalapril (COVE) Study Group Controlled clinical evaluation of enalapril in dogs with heart failure-results of the cooperative veterinary enalapril study group. J Vet Intern Med 1995, 9:243-252.
28. Creager M.A., Cusco J.A. Treatment of congestive heart failure with angiotensin-converting enzyme inhibitors. Heart failure 1995, 316-344. Chapman & Hall, New York. D. McCall, S.H. Rahimtoola (Eds.).
29. Creager M.A., Halperin J.L., Bernard D.B., et al. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation 1981, 64:483-489.
30. Decarli C., Spouse G., Larosa J.L. Serum magnesium levels in symptomatic atrial fibrillation and their relation to rhythm control by intravenous digoxin. Am J Cardiol 1986, 57:956-959.
31. DeFrancesco T.C., Rush J.E., Rozanski E.A., Hansen B.D., Keene B.W., Moore D.T., et al. Prospective clinical evaluation of an ELISA B-type natriuretic peptide assay in the diagnosis of congestive heart failure in dogs presenting with cough or dyspnea. J Vet Intern Med 2007, 21(2):243-250.
32. Dirks J.H., Cirksena W.J., Berliner R.W. Micropuncture study of the effect of various diuretics on sodium reabsorption by the proximal tubules of the dog. J Clin Invest 1966, 45:1875-1885.
33. Dormans T.P., Pickkers P., Russel F.G., et al. Vascular effects of loop diuretics. Cardiovasc Res 1996, 32:988-997.
34. Dormans T.P., van Meyel J.J., Gerlag P.G., et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996, 28:376-382.
35. Dow S.J., Fettman M.J., Smith K.R., et al. Taurine depletion and cardiovascular disease in adult cats fed a potassium-depleted acidified diet. Am J Vet Res 1992, 53:402-405.
36. Dumont A.E., Clauss R.H., Reed G.E., et al. Lymph drainage in patients with congestive heart failure: comparison with findings in hepatic cirrhosis. N Engl J Med 1963, 269:949-952.
37. Dzau V.J., Hollenberg N.K. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med 1984, 100:777-781.
38. Dzau V.J., Swartz S.L. Dissociation of the prostaglandin and renin-angiotensin systems during captopril therapy for chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1987, 60:1101-1105.
39. Dzau V.J., Colucci W.S., Hollenberg N.K., et al. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981, 63:645-651.
40. Dzau V.J., Packer M., Lilly L.S., et al. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984, 310:347-352.
41. Eaton G.E., Cody R.J., Brinkley P.F. Increase in aortic impedance precedes peripheral vasoconstriction at the early stage of ventricular failure in the paced canine model. Circulation 1993, 88:2714-2721.
42. Edwards J.N. Magnesium and congestive heart failure 1991, 679-680. New Orleans.
43. Fenelon G., Protter A.A., Stambler B.S. Examination of the in vivo cardiac electrophysiological effects of nesiritide (human brain natriuretic peptide) in conscious dogs. J Card Fail 2002, 8:320-325.
44. Feuerstein G.Z., Yue T.L., Cheng H.Y., et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl 1993, 11:S41-S48.
45. Fichman M.P., Vorherr H., Kleeman C.R., et al. Diuretic-induced hyponatremia. Ann Intern Med 1971, 75:853-863.
46. Forrester J.S., Diamond G., Chatterjee K., et al. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976, 295:1404-1413.
47. Franciosa J.A., Dunkman W.B., Wilen M., et al. Optimal" left ventricular filling pressure during nitroprusside infusion for congestive heart failure. Am J Med 1983, 74:457-464.
48. Francis G.S., McDonald K.M. Neurohumoral mechanisms in heart failure. Heart failure 1995, 90-116. Chapman & Hall, New York. D. McCall, S.H. Rahimtoola (Eds.).
49. Francis G.S., Goldsmith S.R., Levine T.B., et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984, 101:370-377.
50. Francis G.S., Siegel R.M., Goldsmith S.R., et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985, 103:1-6.
51. Francis G.S. Neurohumoral mechanisms involved in congestive heart failure. Am J Cardiol 1985, 55:15A-21A.
52. Freeman L.M., Rush J.E., Kehayias J.J., et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med 1998, 12:440-448.
53. Freeman R.H., Davis J.D., Williams G.M., et al. Effects of the oral angiotensin converting enzyme inhibitor, SQ 14225 in a model of low cardiac output in dogs. Circ Res 1979, 45:540-545.
54. Friedman E., Shadel M., Halkin H., et al. Thiazide-induced hyponatremia. Ann Intern Med 1989, 110:24-30.
55. Fulop M., Horowitz M., Aberman A., et al. Lactic acidosis in pulmonary edema due to left ventricular failure. Ann Intern Med 1973, 79:180-186.
56. Gaasch W.H., Freeman G.L. Functional properties of normal and failing hearts. Heart failure 1995, 14-29. Chapman & Hall, New York. D. McCall, S.H. Rahimtoola (Eds.).
57. Gerlag P.G.G., van Meijel J.J.M. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med 1988, 148:286-291.
58. Gottlieb S.S., Weir M.R. Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure. Am J Cardiol 1990, 66:14D-21D.
59. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8:136-141.
60. Granger J.P. Regulation of sodium excretion by renal interstitial hydrostatic pressure. Fed Proc 1986, 45:2892-2896.
61. Greco D.S., Biller B., Van Liew C.H. Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J 2003, 44:293-297.
62. Guyton A.C., Lindsey A.W. Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema. Circ Res 1959, 7:649-657.
63. Haggstrom J., Hansson K., Karlberg B.E., et al. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996, 57:1645-1652.
64. Häggström J., Boswood A., O'Grady M., et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008, 22(5):1124-1135.
65. Hall J.E., Guyton A.C., Jackson T.E., et al. Control of glomerular filtration rate by the renin-angiotensin system. Am J Physiol 1977, 233:F366-F372.
66. Hamlin R.L., Smith R.C., Powere T.E., et al. Efficacy of various diuretics in normal dogs. J Am Vet Med Assoc 1965, 146:1417-1420.
67. Heinemann H.O. Right-sided heart failure and the use of diuretics. Am J Med 1978, 64:367-369.
68. Higgins C.B., Vatner S.F., Eckberg D.L., et al. Alterations in the baroreceptor reflex in conscious dogs with heart failure. J Clin Invest 1972, 51715-51724.
69. Hirsch A.T., Muellerleile M., Dzau V.J. Cardiovascular tissue angiotensin systems: activation and actions in heart failure. Heart failure 1995, 117-134. Chapman & Hall, New York. D. McCall, S.H. Rahimtoola (Eds.).
70. Hirsch A.T., Pinto Y.M., Schunkert H., et al. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990, 66:22D-32D.
71. Hollander W., Judson W.E. The relationship of cardiovascular and renal hemodynamic function to sodium excretion in patients with severe heart disease but without edema. J Clin Invest 1956, 35:970-979.
72. Hollenberg N.K. Diuretics in congestive heart failure. Cardiovascular drug therapy 1990, 383-388. WB Saunders, Philadelphia. 2nd ed. F.N. Messerli (Ed.).
73. Ichikawa I., pfeffer J.M., pfeffer M.A., et al. Role of Angiotensin II in the altered renal function of congestive heart failure, Circ Res 1984, 55:669-675.
74. IMPROVE Study Group Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the invasive multicenter prospective veterinary evaluation of enalapril study. J Vet Intern Med 1995, 9:234-242.
75. Jackson E.K. Diuretics. Goodman & Gilman's the pharmacological basis of therapeutics 1996, 685-714. McGraw-Hill, New York. 9th ed. J.G. Hardman, L.E. Limbird, P.B. Molinoff (Eds.).
76. Jensen K.T., Carstens J., Pedersen E.B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998, 274:F63-F72.
77. Jeunesse E., Woehrle F., Schneider M., Lefebvre H.P. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. J Vet Cardiol 2007, 9(2):63-68.
78. Kaloyanides G.J. Pathogenesis and treatment of edema with special reference to the use of diuretics. Clinical disorders of fluid and electrolyte metabolism 1980, 647-701. McGraw-Hill, New York. M.H. Maxwell, C.R. Kleeman (Eds.).
79. Katz A.M. Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med 1990, 322:100-110.
80. Keane W.R., Shapiro B.E. Renal protective effects of angiotensin-converting enzyme inhibition. Am J Cardiol 1990, 65:491-531.
81. Keene B.W., Rush J.E. Therapy of heart failure. Textbook of veterinary internal medicine 1989, 939-975. WB Saunders, Philadelphia. 3rd ed. S.J. Ettinger (Ed.).
82. Khanna C., Lund E.M., Raffe M., et al. Hypomagnesemia in 188 dogs: a hospital population-based prevalence study. J Vet Intern Med 1998, 12:304-309.
83. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2001, 52:11-34.
84. Kinugawa T., Thames M.C. Baroreflexes in heart failure. Heart failure 1995, 30-45. Chapman & Hall, New York. D. McCall, S.H. Rahimtoola (Eds.).
85. Kitagawa H., Wakamiya H., Kitoh K., et al. Efficacy of monotherapy with benazepril, an angiotensin converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency. J Vet Med Sci 1997, 59:513-520.
86. Kittleson M., Keene B., Pion P.D., et al. Results of the multicenter spaniel trial (MUST): taurine and carnitine responsive dilated cardiomyopathy in American cocker spaniels with decreased plasma taurine concentration. J Vet Intern Med 1997, 11:204-211.
87. Knowlen G.G., Kittleson M.D., Nachreiner R.F., et al. Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure. J Am Vet Med Assoc 1983, 183:991-996.
88. Koch J., Pedersen H.D., Jensen A.L., et al. Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy. Res Vet Sci 1995, 59:172-175.
89. Kubo S.H. Neurohormonal activation and the response to converting enzyme inhibitors in congestive heart failure. Circulation 1990, 81(Suppl. III):107-114.
90. Kvart C., Haggstrom J., Pedersen H.D., et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002, 16:80-88.
91. Levens N.R. Control of renal function by intrarenal angiotensin II in the dog. J Cardiovasc Pharmacol 1990, 16(Suppl. 4):565-569.
92. Levin A., Djurdjev O., Barret B., et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001, 38:1398-1407.
93. Levine T.B., Francis G.S., Goldsmith S.R., et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982, 49:1659-1666.
94. Levy M. Effects of acute volume expansion and altered hemodynamics on renal tubular function in chronic caval dogs. J Clin Invest 1972, 51:922-938.
95. Licata G., Di Pasquale P., Parrinello G., et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 2003, 145:459-466.
96. Lifschitz M.D., Schrier R.W. Alterations in cardiac output with chronic constriction of thoracic inferior vena cava. Am J Physiol 1973, 225:1364-1370.
97. Little C.J., Julu P.O., Hansen S., et al. Non-invasive real-time measurements of cardiac vagal tone in dogs with cardiac disease. Vet Rec 2005, 156:101-105.
98. Luis Fuentes V. Use of pimobendan in the management of heart failure. Vet Clin North Am Small Anim Pract 2004, 34:1145-1155.
99. MacDonald K.A., Kittleson M.D., Munro C., et al. Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. J Vet Intern Med 2003, 17:172-177.
100. MacDonald K.A., Kittleson M.D., Kass P.H., White S.D. Effect of spironolactone on diastolic function and left ventricular mass in Maine coon cats with familial hypertrophic cardiomyopathy. J Vet Intern Med 2008, 22(2):335-341.
101. Margulies K.G., Hilderbrand F.L., Lerman A., et al. Increased endothelin in experimental heart failure. Circulation 1990, 82:2226-2232.
102. Mettauer B., Roulearu J.L., Bichet D., et al. Sodium and water excretion abnormalities in congestive heart failure. Ann Intern Med 1986, 105:161-167.
103. Michell A.R. Physiological aspects of the requirement for sodium in mammals. Nutr Res Rev 1989, 2:149-160.
104. Migdal S., Alexander E.A., Levinsky N.G. Evidence that decreased cardiac output is not the stimulus to sodium retention during acute constriction of the vena cava. J Lab Clin Med 1977, 89:809-816.
105. Millard R.W., Higgins C.B., Franklin D., et al. Regulation of the renal circulation during severe exercise in normal dogs and dogs with experimental heart failure. Circ Res 1972, 31:881-888.
106. Miller W.C., Simi W.W., Rice D.L. Contribution of systemic venous hypertension to the development of pulmonary edema in dogs. Circ Res 1978, 43:598-600.
107. Molina C.R., Fowler M.B., McCrory S., et al. Hemodynamic, renal, and endocrine effects of atrial natriuretic peptide infusion in severe heart failure. J Am Coll Cardiol 1988, 12:175-186.
108. Morita H., Suzuki G., Mishima T., et al. Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Cardiovasc Drugs Ther 2002, 16:443-449.
109. Morris M.L., Patton R.L., Teeter S.M. Low sodium diet in heart disease: how low is low?. Vet Med Small Anim Clin 1976, 9:1225-1227.
110. Munagala V.K., Burnett J.C., Redfield M.M. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004, 29:707-769.
111. Naitoh M., Suzuki H., Murakami M., et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994, 267:H2245-H2254.
112. Nomura A., Yasuda H., Minami M., et al. Effect of furosemide in congestive heart failure. Clin Pharmacol Ther 1981, 30:177-182.
113. O'Connor C.M., Gattis W.A., Swedberg K. Current and novel pharmacologic approaches in advanced heart failure. Am Heart J 1998, 135:S249-S263.
114. Oliver J.A., Sciacca R.R., Pinto J., et al. Participation of the prostaglandins in the control of renal blood flow during acute reduction of cardiac output in the dog. J Clin Invest 1981, 67:229-237.
115. Opie L.H., Kaplan N.M. Diuretics. Drugs for the Heart 2005, 80-103. Elsevier/WB Saunders, Philadelphia. 6th ed. L.H. Opie, B.J. Gersh (Eds.).
116. Opie L.H. Heart physiology: from cell to circulation 2003, Lippincott Williams & Wilkins, Baltimore. 4th ed.
117. Osborn J.L., Holdaas H., Thames M.D., et al. Renal adrenoreceptor mediation of antinatriuretic and renin secretion responses to low frequency renal nerve stimulation in the dog. Circ Res 1983, 53:298-305.
118. Oster J.R., Epstein M., Smoller S. Combination therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983, 99:405-406.
119. Packer M., Lee W.H., Kessler P.D. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation 1986, 74:766-774.
120. Packer M., Lee W.H., Medina N., et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987, 106:346-354.
121. Packer M., Lee W.H., Medina N., et al. Influence of renal function on the hemodynamic and clinical responses to long-term captopril therapy in severe chronic heart failure. Ann Intern Med 1986, 104:147-154.
122. Packer M., McMurray J., Massie B.M., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005, 11:12-20.
123. Packer M., Medina N., Yshak M. Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med 1984, 100:782-789.
124. Packer M. Neurohumoral interactions and adaptations in congestive heart failure. Am J Cardiol 1985, 55:1A-10A.
125. Paradiso G., Bakris G.L., Stein J.H. The kidney and heart failure. Heart failure 1995, 135-158. Chapman & Hall, New York. D. McCall, S.H. Rahimtoola (Eds.).
126. Parmley W.W. Pathophysiology of congestive heart failure. Am J Cardiol 1985, 55:9A-14A.
127. Patak R.V., Fadem S.Z., Rosenblatt S.G., et al. Diuretic-induced changes in renal blood flow and prostaglandin E excretion in the dog. Am J Physiol 1979, 236:F494-F500.
128. Pedersen H.D., Koch J., Poulsen K., et al. Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency. J Vet Intern Med 1995, 9:328-331.
129. Pedersen H.D., Schutt T., Sondergaard R., et al. Decreased plasma concentration of nitric oxide metabolites in dogs with untreated mitral regurgitation. J Vet Intern Med 2003, 17:178-184.
130. Pedersen H.D. Effects of mild mitral-valve insufficiency, sodium-intake, and place of blood-sampling on the renin-angiotensin system in dogs. Acta Vet Scand 1996, 37:109-118.
131. Pion P.D., Kittleson M.D. Therapy for feline aortic thromboembolism. Current veterinary therapy X 1989, 295-301. WB Saunders, Philadelphia. R.W. Kirk (Ed.).
132. Pitt B., Zannad F., Remme W.J., et al. The randomized aldactone evaluation study investigators: the effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
133. Pouchelon J.L. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of the multicenter, prospective, randomized, double-blind, placebo-controlled, long term clinical trial. J Vet Cardiol 1999, 1:7-18. (for the Benazepril in Canine Heart Disease Study Group (BENCH).
134. Priebe H., Heimann J.C., Hedley-Whyte J. Effects of renal and hepatic venous congestion on renal function in the presence of low and normal cardiac output in dogs. Circ Res 1980, 47:883-890.
135. Prosek R., Sisson D.D., Oyama M.A., et al. Plasma endothelin-1 immunoreactivity in normal dogs and dogs with acquired heart disease. J Vet Intern Med 2004, 18:840-844.
136. Prosek R., Sisson D.D., Oyama M.A., Solter P.F. Distinguishing cardiac and noncardiac dyspnea in 48 dogs using plasma atrial natriuretic factor, B-type natriuretic factor, endothelin, and cardiac troponin-I. J Vet Intern Med 2007, 21(2):238-242.
137. Reinhardt H.W., Kaczmarczy K.G., Eisele R., et al. Left atrial pressure and sodium balance in conscious dogs on a low sodium intake. Pflugers Arch 1977, 370:59-66.
138. Riegger G.A., Elsner D., Kroner E.P., et al. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanidine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. Circulation 1988, 77:398-406.
139. Riegger G.A., Liebau G., Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 1982, 72:49-52.
140. Riegger G.A., Liebau G., Holzschuh M., et al. Role of the renin-angiotensin system in the development of congestive heart failure in the dog as assessed by chronic converting-enzyme blockade. Am J Cardiol 1984, 53:614-618.
141. Ritz E., Nowack R. Detrimental and beneficial effects of converting enzyme inhibitors on the kidney. J Cardiol Pharmacol 1990, 16(Suppl. 4):570-575.
142. Roche B.M., Schwartz D., Lehnhard R.A., et al. Changes in concentrations of neuroendocrine hormones and catecholamines in dogs with myocardial failure induced by rapid ventricular pacing. Am J Vet Res 2003, 63:1413-1417.
143. Rose B.D., Post T.W. Clinical physiology of acid base and electrolyte disorders 2001, 702. McGraw Hill, New York. 5th ed.
144. Rose B.D., Post T.W. Clinical physiology of acid base and electrolyte disorders 2001, 677. McGraw Hill, New York. 5th ed.
145. Rose B.D. Diuretics. Kidney Int 1991, 39:336-352.
146. Roudebush P., Allen T.A., Kuehn N.F., et al. The effect of combined therapy with captopril, furosemide, and a sodium-restricted diet on serum electrolyte concentrations and renal function in normal dogs and dogs with congestive heart failure. J Vet Intern Med 1994, 8:337-342.
147. Rush J.E., Freeman L.M., Brown D.J., et al. Clinical, echocardiographic, and neurohormonal effects of a sodium-restricted diet in dogs with heart failure. J Vet Intern Med 2000, 14:513-520.
148. Rush J.E., Freeman L.M., Brown D.J., et al. The use of enalapril in the treatment of feline hypertrophic cardiomyopathy. J Am Anim Hosp Assoc 1998, 34:38-41.
149. Ryan M.P. Diuretics and potassium/magnesium depletion: directions for treatment. Am J Med 1987, 82(Suppl. 3A):38-47.
150. Sabbah H.N., Sharov V.G., Gupta R.C., et al. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol 2000, 36:1698-1705.
151. Sabbah H.N., Shimoyama H., Kono T., et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994, 89:2852-2859.
152. Sayer M.B., Atkins C.E., Fujii Y., Adams A.K., DeFrancesco T.C., Keene B.W. Acute effect of pimobendan and furosemide on the circulating renin-angiotensin-aldosterone system in healthy dogs. J Vet Intern Med 2009, 23(5):1003-1006.
153. Schrier R.W., Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577-585.
154. Schrier R.W., Humphreys M.H., Ufferman R.C. Role of cardiac output and the autonomic nervous system in the antinatriuretic response to acute constriction of the thoracic superior vena cava. Circ Res 1971, 29:490-498.
155. Schrier R.W. Pathogenesis of sodium and water retention in high output and low output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy. N Engl J Med 1988, 319:1065-1072. 1127-1134.
156. Seely J.F., Dirks J.H. Site of action of diuretic drugs. Kidney Int 1977, 11:1-8.
157. Shimoyama H., Sabbah H.N., Rosman H., et al. Effects of long-term therapy with enalapril on severity of functional mitral regurgitation in dogs with moderate heart failure. J Am Coll Cardiol 1995, 25:768-772.
158. Sisson D.D. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am Small Anim Pract 2004, 34:1105-1126.
159. Starling E.H. The influence of mechanized factors on lymph production. J Physiol (Lond) 1894, 10:14-155.
160. Staub N.C. Pathophysiology of pulmonary edema. Edema 1984, 719-746. Raven Press, New York. N.C. Staub, A.E. Taylor (Eds.).
161. Suki W.N., Rector F.C., Seldin D.W. The site of action of furosemide and other sulfonamide diuretics in the dog. J Clin Invest 1965, 44:1458-1469.
162. Suki W.N. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Arch Intern Med 1989, 149:669-673.
163. Sun Y., Weber K.T. Cardiac remodelling by fibrous tissue-Role of local factors and circulating hormones. Ann Med 1998, 30(Suppl. 1):S3-S8.
164. Suzuki G., Morita H., Mishima T., et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106:2967-2972.
165. Swales J.D. Magnesium deficiency and diuretics. BMJ 1982, 285:1377-1378.
166. Swan H.J.C., Ganz W., Forrester J., et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 1970, 283:447-451.
167. Tachibana H., Cheng H.J., Ukai T., et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol (Heart Circ Physiol) 2005, 288:H914-H922.
168. Taylor A.E. Capillary fluid filtration: Starling forces and lymph flow. Circ Res 1982, 49:557-575.
169. Thames M.D. Acetylstrophanthidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents. Circ Res 1979, 44:8-15.
170. Thomas C.J., Woods R.L. Haemodynamic action of B-type natriuretic peptide substantially outlasts its plasma half-life in conscious dogs. Clin Exp Pharmacol Physiol 2003, 30:369-375.
171. Thomas J.A., Marks B.H. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978, 41:233-243.
172. Thrall D.E., Calvert C.A. Radiographic evaluation of canine heartworm disease coexisting with right heart failure. Vet Radiol 1983, 24:124-126.
173. Uechi M., Matsuoka M., Kuwajima E., et al. The effects of the loop diuretics furosemide and torsemide on diuresis in dogs and cats. J Vet Med Sci 2003, 65:1057-1061.
174. Uechi M., Sasaki T., Ueno K., et al. Cardiovascular and renal effects of carvedilol in dogs with heart failure. J Vet Med Sci 2002, 64:469-475.
175. van der Zander K., Houben A.J., Kroon A.A., et al. Does brain natriuretic peptide have a direct renal effect in human hypertensives?. Hypertension 2003, 41:119-123.
176. Van Veldhuisen D.J., Genth-Zoth S., Brouwer J., et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998, 32:1811-1818.
177. Vasko M.R., Brown-Cartwright D., Knochel J.P., et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985, 102:314-318.
178. Vollmar A.M., Montag C., Preusser U., et al. Atrial natriuretic peptide and plasma volume of dogs suffering from heart failure or dehydration. Zentralbl Veterinarmed A 1994, 41:548-557.
179. Vollmar A.M., Preusser U., Gerbes A.L., et al. Endothelin concentration in plasma of healthy dogs and dogs with congestive heart failure, renal failure, diabetes mellitus, and hyperadrenocorticism. J Vet Intern Med 1995, 9:105-111.
180. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994, 24:571-575.
181. Ware W.A., Lund D.D., Subieta A.R., et al. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 1990, 197:1475-1481.
182. Watkins L., Burton J.A., Haber E., et al. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 1976, 57:1606-1617.
183. Weaver L.J., Carrico C.J. Congestive heart failure and edema. Edema 1984, 543-562. Raven Press, New York. N.C. Staub, A.E. Taylor (Eds.).
184. Weber K.T. Aldosterone and spironolactone in heart failure [editorial]. N Engl J Med 1999, 341:709-717.
185. Weber K.T. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J Am Coll Cardiol 2004, 44:1308-1310.
186. Wiener-Kronish J.P., Goldstein R., Matthay R.A., et al. Lack of association of pleural effusion with chronic pulmonary arterial and right atrial hypertension. Chest 1987, 92:967-970.
187. Yatsu T., Tomura Y., Tahara A., et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur J Pharmacol 1997, 321:225-230.
188. Zacà V., Rastogi S., Mishra S., Wang M., Sharov V.G., Gupta R.C., et al. Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure. Cardiology 2009, 112(4):294-302.
189. Zucker I.H., Share L., Gilmore J.P. Renal effects of left atrial distension in dogs with chronic congestive heart failure. Am J Physiol 1979, 236:H554-H560.